{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:23:43Z","timestamp":1791300223225,"version":"4.1.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:00:00Z","timestamp":1733443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Relapsing multiple sclerosis (RMS) is a chronic, inflammatory disease of the central nervous system. Ublituximab, an anti-CD20 monoclonal antibody (mAb), is indicated for the treatment of RMS. We performed a systematic literature review (SLR) to identify randomized trials reporting the clinical efficacy and tolerability of ublituximab or comparator disease-modifying therapies (DMTs) for treatment of RMS, and assessed their comparative effects using network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The SLR involved a comprehensive search across various medical databases to identify relevant studies. Included studies were randomized controlled trials (RCTs) of an adult RMS population, focusing on treatment with at least one of ublituximab, alemtuzumab, natalizumab, ocrelizumab, or ofatumumab. For outcomes included in the NMA (annualized relapse rate (ARR), confirmed disability progression (CDP), and treatment discontinuation rate), rate ratios (RR) or hazard ratios (HR), along with their 95% confidence intervals (CIs), were calculated. We performed NMA using a contrast-based random-effects model within a frequentist framework for all outcomes. Ranking probabilities among comparators, and intervention rankings for the NMA, were estimated using surface under the cumulative ranking curve (SUCRA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We included 15 RCTs in the review. For the ARR outcome, there was no statistically significant difference between ublituximab and the other included mAbs [ofatumumab (RR 1.02 (95% CI 0.64\u20131.62)), natalizumab (RR 0.99 (0.59\u20131.65)), alemtuzumab (RR 0.86 (0.51\u20131.46)), and ocrelizumab (RR 0.75 (0.44\u20131.28))]. For CDP at 6 months, our results showed no statistically significant difference between ublituximab and the comparator mAbs [ofatumumab (HR 0.97 (0.49\u20131.92)), natalizumab (HR 1.13 (0.53\u20132.40)), alemtuzumab (HR 1.25 (0.56\u20132.81)), and ocrelizumab (HR 1.29 (0.57\u20132.90))]. For CDP at 3 and 6 months, there was no statistically significant difference between ublituximab and placebo. The all-cause treatment discontinuation rate analysis showed no significant difference between ublituximab and other mAbs, except for alemtuzumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results of this SLR-informed NMA showed that there is no statistically significant difference between ublituximab and the other mAbs in terms of clinical efficacy. Additionally, the findings show that there is no statistically significant difference in discontinuation rates with the exception of the comparison with alemtuzumab, which may be attributed to its unique dosing schedule.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fneur.2024.1479476","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:11Z","timestamp":1733443811000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative efficacy and tolerability of ublituximab vs. other monoclonal antibodies in the treatment of relapsing multiple sclerosis: a systematic review and network meta-analysis of randomized trials"],"prefix":"10.3389","volume":"15","author":[{"given":"Eoin","family":"Moloney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Mashayekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakshi","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Kontogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Ansaripour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wallace","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Paling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Javanbakht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1007\/s00415-021-10744-x","article-title":"Anti-CD20 therapies for multiple sclerosis: current status and future perspectives","volume":"269","author":"Margoni","year":"2022","journal-title":"J Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1126\/science.abj8222","article-title":"Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis","volume":"375","author":"Bjornevik","year":"2022","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet."},{"key":"B4","unstructured":"Nancy\n              Hammond MD\n            \n          \n          12814181\n          Multiple Sclerosis: Fact, Statistics, and you\n          \n          2022"},{"key":"B5","unstructured":"1\n          10\n          \n          \n          2023"},{"key":"B6","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(20)30277-5","article-title":"Cognitive impairment in multiple sclerosis: clinical management, MRI, and therapeutic avenues","volume":"19","author":"Benedict","year":"2020","journal-title":"Lancet Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10072-010-0438-7","article-title":"Treatment options of cognitive impairment in multiple sclerosis","volume":"31","author":"Patti","year":"2010","journal-title":"Neurol Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"144","DOI":"10.18502\/cjn.v21i3.11106","article-title":"Association of cognitive impairment and quality of life in patients with multiple sclerosis: a cross-sectional study","volume":"21","author":"Nabizadeh","year":"2022","journal-title":"Curr J Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"k4674","DOI":"10.1136\/bmj.k4674","article-title":"Disease-modifying therapies for multiple sclerosis","volume":"363","author":"De Angelis","year":"2018","journal-title":"BMJ"},{"key":"B10","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.autrev.2019.05.003","article-title":"Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives","volume":"18","author":"D'Amico","year":"2019","journal-title":"Autoimmun Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1004795","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: from pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual approaches to modulating antibody effector functions and circulation half-life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","article-title":"Considerations for the design of antibody-based therapeutics","volume":"109","author":"Goulet","year":"2020","journal-title":"J Pharm Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e230016","DOI":"10.57264\/cer-2023-0016","article-title":"Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis","volume":"12","author":"Samjoo","year":"2023","journal-title":"J Comp Eff Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs."},{"key":"B16","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s13311-022-01224-9","article-title":"Monoclonal antibodies in the treatment of relapsing multiple sclerosis: an overview with emphasis on pregnancy, vaccination, and risk management","volume":"19","author":"Krajnc","year":"2022","journal-title":"Neurotherapeutics."},{"key":"B17","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/bjh.14534","article-title":"A phase 1\/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab","volume":"177","author":"Sawas","year":"2017","journal-title":"Br J Haematol."},{"key":"B18","unstructured":"DRUGBANK Online"},{"key":"B19","article-title":"Reduced disease progression with ublituximab vs teriflunomide in the phase 3 ULTIMATE I and II studies in relapsing multiple sclerosis","author":"Alvarez","year":"2022","journal-title":"36th Annual Meeting of the Consortium of Multiple Sclerosis Centers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1177\/1352458520918375","article-title":"A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis","volume":"27","author":"Fox","year":"2021","journal-title":"Mult Scler J."},{"key":"B21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med."},{"key":"B22","volume-title":"Systematic Reviews: CRD's Guidance for undertaking reviews in health care","year":"2009"},{"key":"B23","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B26","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/1536867X1501500403","article-title":"Network Meta-analysis","volume":"15","author":"White","year":"2015","journal-title":"Stata J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS ONE."},{"key":"B29","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/jrsm.1045","article-title":"Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression","volume":"3","author":"White","year":"2012","journal-title":"Res Synth Methods."},{"key":"B30","volume-title":"Stata Statistical Software: Release 18","year":"2023"},{"key":"B31","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","article-title":"Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"13","author":"Confavreux","year":"2014","journal-title":"Lancet Neurol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1177\/1352458513507821","article-title":"Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial","volume":"20","author":"Vermersch","year":"2014","journal-title":"Mult Scler J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet."},{"key":"B35","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1016\/S0140-6736(98)03334-0","article-title":"Randomised double-blind placebo-controlled study of interferon-1a in relapsing\/remitting multiple sclerosis","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","article-title":"Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis","volume":"9","author":"Samjoo","year":"2020","journal-title":"J Comp Eff Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.msard.2018.12.040","article-title":"Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis","volume":"29","author":"McCool","year":"2019","journal-title":"Mult Scler Relat Disord."},{"key":"B39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A Randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med."},{"key":"B41","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1177\/1352458510362442","article-title":"Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing\u2014remitting multiple sclerosis","volume":"16","author":"De Stefano","year":"2010","journal-title":"Mult Scler J."},{"key":"B42","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jns.2011.08.013","article-title":"Efficacy and safety of subcutaneous interferon beta-1a in relapsing\u2013remitting multiple sclerosis: further outcomes from the IMPROVE study","volume":"312","author":"De Stefano","year":"2012","journal-title":"J Neurol Sci."},{"key":"B43","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1212\/WNL.53.4.679","article-title":"Evidence of interferon-1a dose response in relapsing-remitting MS the OWIMS study","volume":"53","author":"OWIMS","year":"1999","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1056\/NEJMoa1014656","article-title":"Randomized trial of oral teriflunomide for relapsing multiple sclerosis","volume":"365","author":"O'Connor","year":"2011","journal-title":"N Engl J Med."},{"key":"B45","unstructured":"Novartis\n              (Novartis Pharmaceuticals)\n            \n          \n          Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis (ASCLEPIOS I).\n          \n          2021"},{"key":"B46","unstructured":"Novartis\n              (Novartis Pharmaceuticals)\n            \n          \n          ASCLEPIOS II\n          Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis."},{"key":"B47","unstructured":"Sanofi\n              (Genzyme a SC)\n            \n          \n          Comparison of Alemtuzumab and Rebif\n          \n          2014"},{"key":"B48","unstructured":"Sanofi\n              (Genzyme a SC)\n            \n          \n          Comparison of Alemtuzumab and Rebif\n          \n          2017"},{"key":"B49","unstructured":"Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients with Multiple Sclerosis (TEMSO)\n          \n          \n          \n          2013"},{"key":"B50","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1479476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T00:10:18Z","timestamp":1733443818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2024.1479476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":50,"alternative-id":["10.3389\/fneur.2024.1479476"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2024.1479476","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,6]]},"article-number":"1479476"}}